A team of researchers sought to identify the incidence, antimicrobial susceptibilities, and outcomes associated with bacterial and fungal secondary infections in a large cohort of patients with COVID-19.
The IDSA recommends that antibody therapy should be administered to patients with mild to moderate COVID-19 at high risk for progression to severe disease.
Whether oral vitamin D supplementation in patients who are vitamin D deficient would result in wart clearance was investigated.
A team of investigators conducted a systematic review to determine the bioavailability of oral antibiotics during the initial phase of a systemic infection in hospitalized patients.
Investigators assessed the effectiveness of treatment with methylprednisolone vs dexamethasone for hospitalized COVID-19 patients with hypoxia.
IMPAACT and VESTED assessed pregnancy outcomes and viral suppression status for pregnant women with HIV undergoing treatment with antiretroviral agents.
Farxiga is the first drug to be approved to reduce the risk for many causes of disease, including kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure.
Investigators selected patients with mild COVID-19 to receive either ivermectin or placebo to determine whether ivermectin is an efficacious treatment.
Investigators assessed how critically ill adult patients with COVID-19 and respiratory or cardiovascular organ support responded to tocilizumab or sarilumab treatments.
Patients were randomized to receive either ruxolitinib 5mg twice daily (BID) plus standard of care (SoC), ruxolitinib 15mg BID plus SoC or placebo plus SoC.
